Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Health

Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1

FILE PHOTO: A vial and a syringe are seen in front of a displayed Pfizer logo in this illustration taken November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.

Antibody levels against the subvariant rose nearly nine-fold in older adults, aged 55 and above, who received the Omicron shot compared to a roughly two-fold increase in participants with the original shot, according to data posted on online archive bioRxiv.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.